Epilepsy control with carbamazepine monotherapy from a genetic perspective

Table 6 MTHFR (C677T and A1298C) gene polymorphisms with its relative frequencies in poor seizures controlled and seizure controlled patients at 6^th month of carbamazepine therapy

N = 62	Carbamazepine resistant patients (n = 34)	Carbamazepine responsive patients (n = 28)
Variables	Total	Total
Number (%)	34 (55)	28 (45)
Genotypes
677CC	9	20
677CT	15	5
677TT	10	3
1298AA	11	21
1298 AC	14	4
1298CC	9	3

MTHFR (C677T) Gene
Heterozygous (677CT) genotypes were more likely frequent in carbamazepine resistant patients compared to carbamazepine responsive patients (χ² = 7.5, P = 0.002**) comparing total patients of carbamazepine resistant VS total patients who are responsive to carbamazepine therapy. Similarly, Homozygous(677TT) genotypes were more likely frequent in carbamazepine therapy resistant patients as compared to carbamazepine responsive patients (χ² = 5.9, P = 0.01*).
MTHFR (A1298C) Gene
Heterozygous (1298 AC) genotypes were more likely frequent in carbamazepine resistant patients compared to carbamazepine responsive patients (χ² = 7.03, P = 0.008**) comparing total patients of carbamazepine resistant VS total patients who are responsive to carbamazepine therapy.
Similarly, homozygous (1298CC)genotypes were more likely frequent in carbamazepine therapy resistant patients as compared to carbamazepine responsive patients (χ² = 4.3, P = 0.03*).

ISSN: 2050-6511